Publications by authors named "Akari Takai"

Congenital heart disease (CHD) is common among patients with trisomy 18 (T18), but cardiac surgery has been rarely indicated for T18 patients due to their short life span. Although the therapeutic effects of aggressive interventions were recently demonstrated for T18 patients, the subjects and factors examined varied, resulting in inconsistent findings. Therefore, the effects of cardiac surgery for T18 remain unclear.

View Article and Find Full Text PDF

Genetic defects in ribosome biogenesis result in a group of diseases called ribosomopathies. Patients with ribosomopathies manifest multiorgan phenotypes, including neurological impairments. A well-characterized ribosomopathy, Shwachman-Diamond syndrome (SDS), is mainly associated with loss-of-function mutations in the causal gene SBDS.

View Article and Find Full Text PDF

Developmental and epileptic encephalopathies (DEEs) are the spectrum of severe epilepsies characterized by early-onset, refractory seizures occurring in the context of developmental regression or plateauing. Early infantile epileptic encephalopathy (EIEE) is one of the earliest forms of DEE, manifesting as frequent epileptic spasms and characteristic electroencephalogram findings in early infancy. In recent years, next-generation sequencing approaches have identified a number of monogenic determinants underlying DEE.

View Article and Find Full Text PDF
Article Synopsis
  • The knockdown of the dABCA gene in Drosophila leads to increased social space and hyperactivity in adult flies, but does not affect their climbing ability.
  • The study found that this gene knockdown resulted in an increase in active zones and satellite bouton numbers in motor neuron presynaptic terminals while reducing learning abilities in larvae.
  • The hippo mutation was found to enhance adult hyperactivity but suppress the increase in satellite boutons, suggesting a link between dABCA, lipid transport, and various cellular functions affecting the Hippo signaling pathway.
View Article and Find Full Text PDF

Sorafenib is a promising agent for treating pediatric refractory acute myeloid leukemia (AML) exhibiting FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD); however, its optimal use needs to be established. We report 2 cases of refractory pediatric FLT3-ITD-positive AML treated with sorafenib. Case 1 underwent stem cell transplantation (SCT) without entering remission, despite the use of chemotherapy.

View Article and Find Full Text PDF